Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025)
Eton Pharmaceuticals (ETON) reported Cash from Financing Activities of $421000.0 for Q4 2025, down 98.75% on a YoY basis from $33.6 million in Q4 2024, and up 6.85% sequentially from $394000.0 in Q1 2025.
Eton Pharmaceuticals (ETON) Cash from Financing Activities (2019 - 2025) Analysis & Trends
Eton Pharmaceuticals (ETON) has 7 years of Cash from Financing Activities data on file, last reported at $421000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Financing Activities fell 98.75% year-over-year to $421000.0; the trailing twelve-month figure through Dec 2025 stood at $815000.0 (down 97.5% YoY), and the FY2025 full-year result was $815000.0, down 97.5% from the prior year.
- Cash from Financing Activities improved to $421000.0 in Q4 2025, from $394000.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $33.6 million in Q4 2024 to a low of -$385000.0 in Q1 2022.
- A 5-year average of $1.8 million and a median of -$7000.0 in 2022 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities slumped 1154.29% in 2023 and jumped 11519.05% in 2024, its largest moves.
- Tracing ETON's Cash from Financing Activities over 5 years: stood at $68000.0 in 2021, then surged by 45.59% to $99000.0 in 2022, then sank by 396.97% to -$294000.0 in 2023, then jumped by 11519.05% to $33.6 million in 2024, then slumped by 98.75% to $421000.0 in 2025.
- Business Quant data shows ETON's Cash from Financing Activities at $421000.0 in Q4 2025, $394000.0 in Q1 2025, and $33.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Eton Pharmaceuticals | 1.19 Bn | 1.16 Bn | 13.10 Mn | 421,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 421,000.00 |
| Dec 31, 2025 | 421,000.00 |
| Mar 31, 2025 | 394,000.00 |
| Mar 31, 2025 | 394,000.00 |
| Dec 31, 2024 | 33.57 Mn |
| Dec 31, 2024 | 33.57 Mn |
| Sep 30, 2024 | -385,000.00 |
| Sep 30, 2024 | -385,000.00 |
| Jun 30, 2024 | -216,000.00 |
| Jun 30, 2024 | -216,000.00 |
| Mar 31, 2024 | -378,000.00 |
| Mar 31, 2024 | -378,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Dec 31, 2023 | -294,000.00 |
| Sep 30, 2023 | -369,000.00 |
| Sep 30, 2023 | -369,000.00 |
| Jun 30, 2023 | -245,000.00 |
| Jun 30, 2023 | -245,000.00 |
| Mar 31, 2023 | -49,000.00 |
| Mar 31, 2023 | -49,000.00 |